Stavudine
Stavudine (d4T), sold under the brand name Zerit among others, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. However, it is not a first-line treatment. It is given by mouth.
Clinical data | |
---|---|
Trade names | Zerit |
Other names | 2′,3′-didehydro-2′,3′-dideoxythymidine |
AHFS/Drugs.com | Monograph |
MedlinePlus | a694033 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | >80% |
Protein binding | Negligible |
Metabolism | Kidney elimination (~40%) |
Elimination half-life | 0.8–1.5 hours (in adults) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.169.180 |
Chemical and physical data | |
Formula | C10H12N2O4 |
Molar mass | 224.216 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Common side effects include headache, diarrhea, vomiting, rash, and peripheral nerve problems. Severe side effects include high blood lactate, pancreatitis, and an enlarged liver. It is not generally recommended in pregnancy. Stavudine is in the nucleoside analog reverse-transcriptase inhibitor (NRTI) class of medication.
Stavudine was first described in 1966 and approved for use in the United States in 1994. It is available as a generic medication.